Views

CrossRef citations to date

Altmetric

Original Research

Collagen I enhances the efficiency and anti-tumor activity of dendritic-tumor fusion cells

Jian HeNational Center for International Research of Biological Targeting Diagnosis and Therapy /Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research /Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China

Rong ZhengNational Center for International Research of Biological Targeting Diagnosis and Therapy /Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research /Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China

Zhenghua ZhangNational Center for International Research of Biological Targeting Diagnosis and Therapy /Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research /Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China

Jie TanNational Center for International Research of Biological Targeting Diagnosis and Therapy /Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research /Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China

Chaofan ZhouNational Center for International Research of Biological Targeting Diagnosis and Therapy /Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research /Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China

Guoqing ZhangNational Center for International Research of Biological Targeting Diagnosis and Therapy /Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research /Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China

Xinglu JiangNational Center for International Research of Biological Targeting Diagnosis and Therapy /Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research /Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China

Qianyi SunNational Center for International Research of Biological Targeting Diagnosis and Therapy /Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research /Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China

Sufang ZhouNational Center for International Research of Biological Targeting Diagnosis and Therapy /Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research /Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China

Duo ZhengShenzhen Key Laboratory of Translational Medicine of Tumor, Department of Basic Medicine, School of Medicine, Shenzhen University, Shenzhen, Guangdong, China

Yong HuangNational Center for International Research of Biological Targeting Diagnosis and Therapy /Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research /Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China

Lige WuNational Center for International Research of Biological Targeting Diagnosis and Therapy /Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research /Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China

Zongqiang LaiNational Center for International Research of Biological Targeting Diagnosis and Therapy /Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research /Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China

Jieping LiNational Center for International Research of Biological Targeting Diagnosis and Therapy /Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research /Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China

Nuo YangNational Center for International Research of Biological Targeting Diagnosis and Therapy /Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research /Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China

Xiaoling LuNational Center for International Research of Biological Targeting Diagnosis and Therapy /Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research /Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, China

Yongxiang ZhaoNational Center for International Research of Biological Targeting Diagnosis and Therapy /Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research /Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi, ChinaCorrespondence[email protected] [email protected] [email protected]

show all

ABSTRACT

Low fusion efficiency and nominal activity of fusion cells (FCs) restrict the clinical application of dendritic cell (DC)/tumor fusion cells. Collagen I (Col I) is an interstitial collagen with a closely-knit structure used to repair damaged cell membranes. This study evaluated whether Col I could improve the fusion efficiency of polyethylene glycol (PEG)-induction and enhance the immunogenicity of fusion vaccine. DC/B16 melanoma and controlled DC/H22 hepatoma cell fusions were induced by PEG with or without Col I. Col I/PEG treatment increased the levels of DC surface molecules and the secretion of lactate, pro- and anti-inflammatory cytokines in fusion cells. Col I/PEG-treated FCs enhanced T-cell proliferation and cytotoxic T lymphocyte activity. The Col I-prepared fusion vaccine obviously suppressed tumor growth and prolonged mice survival time. Thus Col I treatment could significantly improve the efficiency of PEG-induced DC/tumor fusion and enhance the anticancer activity of the fusion vaccine. This novel fusion strategy might promote the clinical application of DC/tumor fusion immunotherapy.

KEYWORDS:

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed

Funding

This work was supported, in part, by grants from Programs for Changjiang Scholars and Innovative Research Team in University (No. IRT_15R13); Key Project of National Natural Scientific Foundation of China (No. 81430055); International Cooperation Project of the Ministry of Science and Technology of China (No. 2015DFA31320); the Project for Innovative Research Team in Guangxi Natural Science Foundation (2015GXNSFFA139001); the Project of Science and Technology of Guangxi (Nos. 14125008–2–12 and 1599005–2–10); Guangxi Natural Science Foundation (2015GXNSFAA139217 and 2016GXNSFAA380231); The Scientific Research Fund of Guangxi Education Department (No. YB2014057) and Guangxi Education Department Grant entitled “Innovation Project of Guangxi Graduate Education.”

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Collagen I enhances the efficiency and anti-tumor activity of dendritic-tumor fusion cells

Information for

Open access

Opportunities

Help and information

Collagen I enhances the efficiency and anti-tumor activity of dendritic-tumor fusion cells

ABSTRACT

Disclosure of potential conflicts of interest

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature